Indication
Renal cell carcinoma
Renal cell carcinoma is a primary malignant neoplasm of the urinary system that originates from the epithelial lining of the renal tubules and accounts for the vast majority of adult kidney cancers. Read more about Renal cell carcinoma
45 drugs 31 manufacturers
Drugs that treat it
Common Renal cell carcinoma therapies.
LENVIMA (lenvatinib mesylate)
CABOMETYX (cabozantinib s-malate)
VOTRIENT (pazopanib HCl)
BAVENCIO (avelumab)
DEPO-PROVERA (medroxyprogesterone acetate)
TORISEL (temsirolimus)
DEPO-PROVERA (medroxyprogesterone acetate)
TEMSIROLIMUS
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRenal cell carcinoma is a primary malignant neoplasm of the urinary system that originates from the epithelial lining of the renal tubules and accounts for the vast majority of adult kidney cancers.
Primarily affecting older adults with a male predominance, the disease encompasses several histologic subtypes, most commonly clear cell renal cell carcinoma, which is frequently driven by alterations in the von Hippel–Lindau tumor suppressor pathway and increased tumor vascularity.
Although many cases are detected incidentally on abdominal imaging, clinical manifestations can include hematuria, flank pain, a palpable abdominal mass, fatigue, unexplained weight loss, and various paraneoplastic syndromes.
- cancer.gov
Renal cell carcinoma is a primary malignant neoplasm of the urinary system that originates from the epithelial lining of the renal tubules and accounts for the vast majority of adult kidney cancers
- nih.gov
Renal cell carcinoma is a primary malignant neoplasm of the urinary system that originates from the epithelial lining of the renal tubules and accounts for the vast majority of adult kidney cancers Primarily affecting older adults with a male predominance, the disease encompasses several histologic subtypes, most commonly clear cell renal cell carcinoma, which is frequently driven by alterations in the von Hippel–Lindau tumor suppressor pathway and increased tumor vascularity
- nih.gov
Primarily affecting older adults with a male predominance, the disease encompasses several histologic subtypes, most commonly clear cell renal cell carcinoma, which is frequently driven by alterations in the von Hippel–Lindau tumor suppressor pathway and increased tumor vascularity Although many cases are detected incidentally on abdominal imaging, clinical manifestations can include hematuria, flank pain, a palpable abdominal mass, fatigue, unexplained weight loss, and various paraneoplastic sy...
- nih.gov
Primarily affecting older adults with a male predominance, the disease encompasses several histologic subtypes, most commonly clear cell renal cell carcinoma, which is frequently driven by alterations in the von Hippel–Lindau tumor suppressor pathway and increased tumor vascularity
- medlineplus.gov
Although many cases are detected incidentally on abdominal imaging, clinical manifestations can include hematuria, flank pain, a palpable abdominal mass, fatigue, unexplained weight loss, and various paraneoplastic syndromes
- nih.gov
Although many cases are detected incidentally on abdominal imaging, clinical manifestations can include hematuria, flank pain, a palpable abdominal mass, fatigue, unexplained weight loss, and various paraneoplastic syndromes
- mayoclinic.org
Although many cases are detected incidentally on abdominal imaging, clinical manifestations can include hematuria, flank pain, a palpable abdominal mass, fatigue, unexplained weight loss, and various paraneoplastic syndromes
Personalize your experience
Follow Renal cell carcinoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.